HLA-C and neoplasm: Combined exome sequencing with neoantigen prediction algorithms (based on major histocompatibility complex [MHC] binding avidity comparing mutated to wild-type peptides) identified those tumor-specific mutant antigens (TSMA) or “neoantigens” that were specifically targeted by the immune system to effect elimination of growing tumors62.